Overview
Evocalcet has been used in trials studying the treatment of Hyperparathyroidism and Secondary Hyperparathyroidism.
Background
Evocalcet has been used in trials studying the treatment of Hyperparathyroidism and Secondary Hyperparathyroidism.
Indication
⑴用于慢性肾病（CKD）维持性透析患者继发性甲状旁腺功能亢进（SHPT）的治疗。 ⑵用于治疗甲状旁腺癌相关高钙血症或无法切除或术后复发的原发性甲状旁腺功能亢进患者。 SHPT是指各种原因所致的低血钙或高血磷刺激甲状旁腺过度分泌甲状旁腺素而引发的综合征。各种原因引起的1,25(OH)2D3缺乏、低钙血症和高磷血症均可导致SHPT。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Evocalcet Tablets | 国药准字HJ20240035 | 化学药品 | 片剂 | 7/30/2024 | |
| Evocalcet Tablets | 国药准字HJ20240034 | 化学药品 | 片剂 | 7/30/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| ♐♇ ORKEDIA TABLETS 2MG | N/A | N/A | N/A | 10/25/2024 | |
| ♐♇ ORKEDIA TABLETS 1MG | N/A | N/A | N/A | 10/25/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||